Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.

Pohorelic B, Singh R, Parkin S, Koro K, Yang AD, Egan C, Magliocco A.

Breast Cancer Res Treat. 2012 May;133(1):201-14. doi: 10.1007/s10549-011-1753-2. Epub 2011 Sep 6. Erratum in: Breast Cancer Res Treat. 2012 May;133(1):215-6.

PMID:
21894461
2.

Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration.

Koro K, Parkin S, Pohorelic B, Yang AD, Narendran A, Egan C, Magliocco A.

Breast Cancer Res Treat. 2011 Feb;126(1):73-83. doi: 10.1007/s10549-010-0889-9. Epub 2010 Apr 17.

PMID:
20401631
3.

Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.

Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R.

Cancer Res. 2007 Mar 15;67(6):2800-8.

4.

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI.

Breast Cancer Res Treat. 2006 Jun;97(3):263-74. Epub 2005 Dec 7.

PMID:
16333527
5.

Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.

Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP.

Mol Cancer Ther. 2010 Jun;9(6):1629-37. doi: 10.1158/1535-7163.MCT-09-1058. Epub 2010 May 18.

6.

Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.

Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, Marchiò S, Aglietta M, Leone F.

Mol Cancer Ther. 2012 Jul;11(7):1528-38. doi: 10.1158/1535-7163.MCT-11-1020. Epub 2012 Mar 27.

7.

Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models.

Mutrie JC, Chambers AF, Tuck AB.

Cancer Biol Ther. 2011 Oct 15;12(8):680-90. doi: 10.4161/cbt.12.8.16440. Epub 2011 Oct 15.

PMID:
21795853
8.

Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone.

Liu S, Goldstein RH, Scepansky EM, Rosenblatt M.

Cancer Res. 2009 Nov 15;69(22):8742-51. doi: 10.1158/0008-5472.CAN-09-1541. Epub 2009 Nov 3.

9.

Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.

Sánchez-Bailón MP, Calcabrini A, Gómez-Domínguez D, Morte B, Martín-Forero E, Gómez-López G, Molinari A, Wagner KU, Martín-Pérez J.

Cell Signal. 2012 Jun;24(6):1276-86.

PMID:
22570868
10.

PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.

Ma JG, Huang H, Chen SM, Chen Y, Xin XL, Lin LP, Ding J, Liu H, Meng LH.

Breast Cancer Res Treat. 2011 Nov;130(1):85-96. doi: 10.1007/s10549-010-1302-4. Epub 2010 Dec 22.

PMID:
21181437
11.

A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.

Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA.

Cancer Res. 2007 Feb 15;67(4):1580-8.

12.

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.

Saad F, Lipton A.

Cancer Treat Rev. 2010 Apr;36(2):177-84. doi: 10.1016/j.ctrv.2009.11.005. Epub 2009 Dec 16. Review.

PMID:
20015594
13.

Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells.

Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, Kozuka Y, Ogawa T, Shiraishi T, Imanaka-Yoshida K.

Am J Pathol. 2011 Feb;178(2):754-63. doi: 10.1016/j.ajpath.2010.10.015.

14.

Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.

Dong M, Rice L, Lepler S, Pampo C, Siemann DW.

Anticancer Res. 2010 Nov;30(11):4405-13.

PMID:
21115886
15.

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.

Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, Fuqua SA.

Mol Cancer Ther. 2006 Dec;5(12):3023-31.

16.

Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer.

Guo D, Huang J, Gong J.

Mol Cell Biochem. 2012 Apr;363(1-2):179-90. doi: 10.1007/s11010-011-1170-1. Epub 2011 Dec 14.

PMID:
22167620
17.

Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.

Amemiya Y, Yang W, Benatar T, Nofech-Mozes S, Yee A, Kahn H, Holloway C, Seth A.

Breast Cancer Res Treat. 2011 Apr;126(2):373-84. doi: 10.1007/s10549-010-0921-0. Epub 2010 May 13.

PMID:
20464481
18.

The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.

Bartscht T, Lehnert H, Gieseler F, Ungefroren H.

Cancer Chemother Pharmacol. 2012 Aug;70(2):221-30. doi: 10.1007/s00280-012-1904-0. Epub 2012 Jun 15.

PMID:
22699812
19.

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.

Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI.

Breast Cancer Res Treat. 2009 May;115(1):57-67. doi: 10.1007/s10549-008-0058-6. Epub 2008 May 21.

PMID:
18493848
20.

PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.

Glondu-Lassis M, Dromard M, Lacroix-Triki M, Nirdé P, Puech C, Knani D, Chalbos D, Freiss G.

Cancer Res. 2010 Jun 15;70(12):5116-26. doi: 10.1158/0008-5472.CAN-09-4368. Epub 2010 May 25.

Supplemental Content

Support Center